Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Mature T- and natural killer (NK)-cell neoplasms are heterogeneous disorders with poor prognoses.
• Current first-line chemotherapy results are often unsatisfactory for common T-cell lymphomas.
• Autologous hematopoietic stem cell transplantation (HSCT) is recommended but not feasible for all patients due to early relapse or refractoriness.

Purpose of the Study:

• To review the role of allogeneic HSCT in managing relapsed and refractory T-cell lymphomas.
• To discuss the challenges and future directions in T- and NK-cell neoplasm treatment.

Main Methods:

• Review of current treatment strategies for mature T- and NK-cell neoplasms.
• Analysis of the efficacy and challenges of allogeneic HSCT.
• Discussion of emerging targeted therapies and their integration with transplantation.

Main Results:

• Allogeneic HSCT can induce long-lived remissions in 30-50% of eligible relapsed/refractory T-cell lymphoma patients.
• Haploidentical HSCT is expanding transplantation eligibility.
• Optimal integration of new drugs and prospective studies for allogeneic HSCT are needed.

Conclusions:

• Allogeneic HSCT remains a valuable option for relapsed/refractory T-cell lymphomas.
• Reducing morbidity and mortality associated with allogeneic HSCT is crucial.
• Further research is urgently needed to optimize treatment strategies, including novel drug integration and prospective studies.